fluorouracil has been researched along with Cardiovascular Abnormalities in 1 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Cardiovascular Abnormalities: Congenital, inherited, or acquired anomalies of the CARDIOVASCULAR SYSTEM, including the HEART and BLOOD VESSELS.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Steenbruggen, TG | 1 |
Steggink, LC | 1 |
Seynaeve, CM | 1 |
van der Hoeven, JJM | 1 |
Hooning, MJ | 1 |
Jager, A | 1 |
Konings, IR | 1 |
Kroep, JR | 1 |
Smit, WM | 1 |
Tjan-Heijnen, VCG | 1 |
van der Wall, E | 1 |
Bins, AD | 1 |
Linn, SC | 1 |
Schaapveld, M | 1 |
Jacobse, JN | 1 |
van Leeuwen, FE | 1 |
Schröder, CP | 1 |
van Tinteren, H | 1 |
de Vries, EGE | 1 |
Sonke, GS | 1 |
Gietema, JA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-up of a Randomized Phase III Study[NCT03087409] | 885 participants (Actual) | Observational | 2016-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for fluorouracil and Cardiovascular Abnormalities
Article | Year |
---|---|
High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial.
Topics: Adult; Axilla; Breast; Breast Neoplasms; Cardiovascular Abnormalities; Child; Cyclophosphamide; Dise | 2020 |